Treatment of osteosarcoma. The Scandinavian Sarcoma Group experience

Cancer Treatment and Research

Volumn 152, Issue , 2009, Pages 309-318

  Bruland, Øyvind S ^a   Bauer, Henrik ^a   Alvegaard, Thor ^a   Smeland, Sigbjørn ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE;

CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG RESPONSE; EVENT FREE SURVIVAL; HUMAN; LIMB SALVAGE; MICROMETASTASIS; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SCANDINAVIA; ADULT; AGED; BONE NEOPLASMS; CLINICAL TRIAL (TOPIC); FEMALE; MALE; MIDDLE AGED; MORTALITY;

ADULT; AGED; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOSARCOMA; PROGNOSIS;

EID: 77953668096     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0284-9_16     Document Type: Conference Paper

References (15)

1. Malawer MM, Helman LJ, O'Sullivan B. Sarcomas of bone. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer - Principles & Practice of Oncology. 7th ed. Philadelphia: Lippincott-Raven Publishers; 2005:1638-1686.
2. Souhami R, Cannon SR. Osteosarcoma. In: Peckham M, Pinedo HM, Veronesi U, eds. Oxford Textbook of Oncology. Oxford: Oxford University Press; 1995:1969-1976.
3. Huvos AG. Osteogenic sarcoma. In: Huvos AG, ed. Bone Tumors. Diagnosis, Treatment and Prognosis. Philadelphia: WB Saunders; 1991:85-155.
4. Dahlin D, Unni K. Osteogenic sarcoma of bone and its important recognizable varieties. Am J Surg Pathol. 1977;1:61-72.
5. Bruland OS, Pihl A. On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer. 1997;33(11):1725-1731.
6. Cade S. Osteogenic sarcoma: a study based on 133 patients. J R Coll Surg Edinb. 1955;1:79-111.
7. Rosen G, Marcove RC, Caparros B. Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163-2177.
8. Del Prever AB, Smeland S, Tienghi A, et al. High-risk osteosarcoma (OS): preliminary results of the ISG-SSG II protocol. ASCO Meet Abstr. 2005;23(26):9002.
9. Saeter G, Alvegard TA, Elomaa I, Stenwig AE, et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol. 1991;9:1766-1775.
10. Smeland S, Muller C, Alvegard TA, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39:488-494.
11. Ferrari S, Smeland S, Mercury M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845-8852.
12. Alvegård TA, Rydholm A, eds. The Scandinavian Sarcoma Group. 25 years' experience. Acta Orthop Scand. 2004;75(Suppl 311):1-114.
13. Saeter G, Bruland OS, Follerås G, et al. Extremity and non-extremity high-grade osteosarcoma - the Norwegian Radium Hospital experience during the modern chemotherapy era. Acta Oncol. 1996;35(Suppl 8):129-134.
14. Sæter G and Bruland, ØS. High-grade osteosarcoma: The scope beyond the classical patient. 21-23 In: Towards the Eradication of Osteosarcoma Metastases - An Odyssey; 1998. ISBN 82-91929-02-5
15. Bruland ØS, Kleppe H, Sæter G, et al. Hematogenous micrometases in osteosarcoma patients. Clin Cancer Res. 2005;11(13):4666-4673.